Key PointsBridgeBio saw revenue climb by 193% year over year in the third quarter.

Should You Invest $1,000 in BridgeBio Pharma Right Now?

BridgeBio Pharma, Inc. reported its financial results for the third quarter ended September 30, 2026, with total revenues of $353.2 million, primarily comprised of $253.2 million of U.S. Attruby net product revenue, which was up approximately $31 million sequentially and $145 mil

BridgeBio Pharma, Inc. Reports Third Quarter 2026 Financial Results and Corporate Updates

(RTTNews) - The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.

Biotech Stocks Facing FDA Decision In November 2026 

(RTTNews) - On Sunday, BridgeBio Pharma, Inc. (BBIO), a biopharmaceutical company, presented additional Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1. The findings were presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meet

BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism 

(RTTNews) - BridgeBio Pharma, Inc. (BBIO) announced the presentation of new real-world and Phase 3 data on acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.

BridgeBio Highlights Attruby Data Showing Lower Hospitalization Risk In ATTR-CM At HFSA 2026 

(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

BridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis 

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc. News